M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe

Biochemical Pharmacology

Volumn 82, Issue 11, 2011, Pages 1604-1618

  Evison, Benny J ^a   Pastuovic, Mile ^a   Bilardi, Rebecca A ^a   Forrest, Robert A ^a   Pumuye, Paul P ^a   Sleebs, Brad E ^b   Watson, Keith G ^b   Phillips, Don R ^a   Cutts, Suzanne M ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Anthracenedione; Checkpoint kinase; Double strand break; Mitotic catastrophe; Topoisomerase II

Indexed keywords

5,8 DIHYDROXY ANTHRACENEDIONE DERIVATIVE; ANTHRAQUINONE; ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; HISTONE H2AX; M 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; DNA BINDING; DNA DAMAGE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL;

ANIMALS; ANTHRAQUINONES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CATTLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HISTONES; HUMANS; MITOSIS; PERMEABILITY; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES; STAUROSPORINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80255123487     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.08.013     Document Type: Article

References (57)

1. J.F. Bishop Cancer facts: a concise oncology text 1999 Harwood Academic Australia
2. V.T. DeVita, S. Hellman, and S.A. Rosenberg Cancer: principles & practice of oncology 2001 Lippincott Williams & Wilkins Philadelphia; London
3. D. Faulds, J.A. Balfour, P. Chrisp, and H.D. Langtry Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer Drugs 41 1991 400 449 (Pubitemid 21920736)
4. D. Mukherji, and R. Pettengell Pixantrone for the treatment of aggressive non-Hodgkin lymphoma Expert Opin Pharmacother 11 2010 1915 1923
5. L.A. Hazlehurst, A.P. Krapcho, and M.P. Hacker Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones Cancer Lett 91 1995 115 124
6. P. De Isabella, M. Palumbo, C. Sissi, G. Capranico, N. Carenini, and E. Menta Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide- anthracenedione derivatives Mol Pharmacol 48 1995 30 38
7. J. Kapuscinski, and Z. Darzynkiewicz Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids Proc Natl Acad Sci USA 83 1986 6302 6306 (Pubitemid 17174724)
8. A. Feofanov, S. Sharonov, F. Fleury, I. Kudelina, and I. Nabiev Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes Biophys J 73 1997 3328 3336 (Pubitemid 27525795)
9. F.E. Durr, R.E. Wallace, and R.V. Citarella Molecular and biochemical pharmacology of mitoxantrone Cancer Treat Rev 10 Suppl. B 1983 3 11 (Pubitemid 14150764)
10. L.A. Hazlehurst, A.P. Krapcho, and M.P. Hacker Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells Biochem Pharmacol 50 1995 1087 1094
11. P.J. Smith, S.A. Morgan, M.E. Fox, and J.V. Watson Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells Biochem Pharmacol 40 1990 2069 2078 (Pubitemid 20346458)
12. L.A. Zwelling, J. Mayes, E. Altschuler, P. Satitpunwaycha, T.R. Tritton, and M.P. Hacker Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II Biochem Pharmacol 46 1993 265 271 (Pubitemid 23218611)
13. A. Skladanowski, and J. Konopa Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells Br J Cancer 82 2000 1300 1304 (Pubitemid 30145349)
14. A.L. Ellis, J.K. Randolph, B.R. Conway, and D.A. Gewirtz Biochemical lesions in DNA associated with the antiproliferative effects of mitoxantrone in the hepatoma cell Biochem Pharmacol 39 1990 1549 1556 (Pubitemid 20157841)
15. B.S. Parker, C. Cullinane, and D.R. Phillips Formation of DNA adducts by formaldehyde-activated mitoxantrone Nucleic Acids Res 27 1999 2918 2923 (Pubitemid 29335713)
16. B.J. Evison, O.C. Mansour, E. Menta, D.R. Phillips, and S.M. Cutts Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent Nucleic Acids Res 35 2007 3581 3589 (Pubitemid 47244653)
17. B.S. Parker, A. Rephaeli, A. Nudelman, D.R. Phillips, and S.M. Cutts Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation Oncol Res 14 2004 279 290 (Pubitemid 38758106)
18. B.J. Evison, F. Chiu, G. Pezzoni, D.R. Phillips, and S.M. Cutts Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets Mol Pharmacol 74 2008 184 194 (Pubitemid 351872169)
19. B.S. Parker, T. Buley, B.J. Evison, S.M. Cutts, G.M. Neumann, and M.N. Iskander A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences J Biol Chem 279 2004 18814 18823 (Pubitemid 38623308)
20. O.C. Mansour, B.J. Evison, B.E. Sleebs, K.G. Watson, A. Nudelman, and A. Rephaeli New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation J Med Chem 53 2010 6851 6866
21. L.H. Hurley DNA and its associated processes as targets for cancer therapy Nat Rev Cancer 2 2002 188 200 (Pubitemid 37328788)
22. F.E. Durr Biochemical pharmacology and tumor biology of mitoxantrone and ametantrone J.W. Lown, Anthracycline and anthracenedione-based anticancer agents 1988 Elsevier Amsterdam, The Netherlands 163 200
23. K.C. Murdock, R.G. Child, P.F. Fabio, R.B. Angier, R.E. Wallace, and F.E. Durr Antitumor agents. 1. 1,4-bis[(aminoalkyl)amino]-9,10-anthracenediones J Med Chem 22 1979 1024 1030 (Pubitemid 10226789)
24. R.K. Zee-Cheng, and C.C. Cheng Antineoplastic agents structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones J Med Chem 21 1978 291 294 (Pubitemid 8293629)
25. A.P. Krapcho, M.E. Petry, Z. Getahun, J.J. Landi Jr., J. Stallman, and J.F. Polsenberg 6,9-bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations J Med Chem 37 1994 828 837 (Pubitemid 24123481)
26. H.C. Reinhardt, A.S. Aslanian, J.A. Lees, and M.B. Yaffe p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage Cancer Cell 11 2007 175 189 (Pubitemid 46209849)
27. S.P. Jackson, and J. Bartek The DNA-damage response in human biology and disease Nature 461 2009 1071 1078
28. I.B. Roninson, E.V. Broude, and B.D. Chang If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells Drug Resist Updat 4 2001 303 313 (Pubitemid 34456384)
29. T.C. Jenkins Optical absorbance and fluorescence techniques for measuring DNA-drug interactions Methods Mol Biol 90 1997 195 218
30. A. Haldane, and D.M. Sullivan DNA topoisomerase II-catalyzed DNA decatenation Methods Mol Biol 95 2001 13 23
31. L.P. Swift, A. Rephaeli, A. Nudelman, D.R. Phillips, and S.M. Cutts Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death Cancer Res 66 2006 4863 4871
32. S.H. MacPhail, J.P. Banath, T.Y. Yu, E.H. Chu, H. Lambur, and P.L. Olive Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays Int J Radiat Biol 79 2003 351 358 (Pubitemid 36920536)
33. M. Ugarenko, A. Nudelman, A. Rephaeli, K. Kimura, D.R. Phillips, and S.M. Cutts ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts Biochem Pharmacol 79 2010 339 349
34. B.E. Loveland, T.G. Johns, I.R. Mackay, F. Vaillant, Z.X. Wang, and P.J. Hertzog Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays Biochem Int 27 1992 501 510
35. B.J. Evison, R.A. Bilardi, F.C. Chiu, G. Pezzoni, D.R. Phillips, and S.M. Cutts CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity Nucleic Acids Res 37 2009 6355 6370
36. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
37. P.J. Smith, R. Desnoyers, N. Blunt, Y. Giles, L.H. Patterson, and J.V. Watson Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation Cytometry 27 1997 43 53 (Pubitemid 27059781)
38. J. Basra, C.R. Wolf, J.R. Brown, and L.H. Patterson Evidence for human liver mediated free-radical formation by doxorubicin and mitozantrone Anticancer Drug Des 1 1985 45 52 (Pubitemid 16102376)
39. X. Huang, A. Kurose, T. Tanaka, F. Traganos, W. Dai, and Z. Darzynkiewicz Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine Cancer Biol Ther 5 2006 959 964
40. K. Bojanowski, S. Lelievre, J. Markovits, J. Couprie, A. Jacquemin-Sablon, and A.K. Larsen Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells Proc Natl Acad Sci USA 89 1992 3025 3029
41. W.G. Harker, D.L. Slade, R.L. Parr, P.W. Feldhoff, D.M. Sullivan, and M.H. Holguin Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line Cancer Res 55 1995 1707 1716
42. W.M. Bonner, C.E. Redon, J.S. Dickey, A.J. Nakamura, O.A. Sedelnikova, and S. Solier GammaH2AX and cancer Nat Rev Cancer 8 2008 957 967
43. T. Godard, E. Deslandes, F. Sichel, J.M. Poul, and P. Gauduchon Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay Mutat Res 520 2002 47 56 (Pubitemid 35247572)
44. J.H. Doroshow, and K.J. Davies Comparative cardiac oxygen radical metabolism by anthracycline antibiotics, mitoxantrone, bisantrene, 4′-(9-acridinylamino)-methanesulfon-m-anisidide, and neocarzinostatin Biochem Pharmacol 32 1983 2935 2939 (Pubitemid 13013730)
45. K. Reszka, J.A. Hartley, P. Kolodziejczyk, and J.W. Lown Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Evidence for covalent binding of 14C-labeled drug Biochem Pharmacol 38 1989 4253 4260 (Pubitemid 20009024)
46. M. Lobrich, A. Shibata, A. Beucher, A. Fisher, M. Ensminger, and A.A. Goodarzi GammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization Cell Cycle 9 2010 662 669
47. J.L. Nitiss Targeting DNA topoisomerase II in cancer chemotherapy Nat Rev Cancer 9 2009 338 350
48. G. Capranico, M. Binaschi, M.E. Borgnetto, F. Zunino, and M. Palumbo A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons Trends Pharmacol Sci 18 1997 323 329 (Pubitemid 27404659)
49. S. Burma, B.P. Chen, M. Murphy, A. Kurimasa, and D.J. Chen ATM phosphorylates histone H2AX in response to DNA double-strand breaks J Biol Chem 276 2001 42462 42467
50. N. Bucher, and C.D. Britten G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer Br J Cancer 98 2008 523 528 (Pubitemid 351214533)
51. W.A. Cliby, K.A. Lewis, K.K. Lilly, and S.H. Kaufmann S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function J Biol Chem 277 2002 1599 1606 (Pubitemid 34968919)
52. I.M. Ward, and J. Chen Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress J Biol Chem 276 2001 47759 47762
53. A. Jazayeri, J. Falck, C. Lukas, J. Bartek, G.C. Smith, and J. Lukas ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks Nat Cell Biol 8 2006 37 45 (Pubitemid 43064795)
54. P.J. Hurley, and F. Bunz ATM and ATR: components of an integrated circuit Cell Cycle 6 2007 414 417 (Pubitemid 46393443)
55. K. Seiter Toxicity of the topoisomerase II inhibitors Expert Opin Drug Saf 4 2005 219 234 (Pubitemid 40867335)
56. E.A. Kohn, N.D. Ruth, M.K. Brown, M. Livingstone, and A. Eastman Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation J Biol Chem 277 2002 26553 26564 (Pubitemid 34967153)
57. B.B. Zhou, and S.J. Elledge The DNA damage response: putting checkpoints in perspective Nature 408 2000 433 439